Detection of epidermal growth factor receptor gene mutations in cytology specimens from patients with non-small cell lung cancer utilising high-resolution melting amplicon analysis

被引:73
作者
Smith, G. D. [1 ]
Chadwick, B. E. [2 ]
Willmore-Payne, C. [1 ]
Bentz, J. S. [2 ]
机构
[1] Associated Reg & Univ Pathologists Labs Inc, Inst Clin & Expt Pathol, Salt Lake City, UT USA
[2] Univ Utah, Dept Pathol, Salt Lake City, UT USA
关键词
D O I
10.1136/jcp.2007.051425
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Background: Activating epidermal growth factor receptor ( EGFR) mutations have been implicated in non-small cell lung cancer (NSCLC), and have also been clinically correlated with patient sensitivity to targeted EGFR inhibitors. Aim: To describe a technique for determining EGFR mutation status on archival fine needle aspirate (FNA) specimens from advanced NSCLC patients. Methods: Eleven archival FNA slides from patients with advanced NSCLC were examined for diagnostic material to identify tumour cell-enriched regions. EGFR mutation status was determined using a slide-scrape DNA extraction protocol of selected tumour cell regions on the smear slides, followed by real time PCR and high resolution melt analysis (HRMAA) of EGFR exons 18, 19, 20, and 21, followed by sequence analysis. Results: All DNA samples were successfully amplified by PCR. Three adenocarcinoma patient samples contained EGFR mutations in exon 19 (L747-P753insS). One of the three had an additional exon 19 mutation (A755D). Conclusions: Archival cytology slides from patients with NSCLC can be used to determine EGFR mutation status by PCR, HRMAA, and sequencing. The ability to use archival cytology slides greatly increases the potential material available for molecular analysis in diagnosis and selection of patients for targeted therapeutic agents.
引用
收藏
页码:487 / 493
页数:7
相关论文
共 30 条
[11]   Epidermal growth factor independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression [J].
Jiang, JR ;
Greulich, H ;
Jänne, PA ;
Sellers, WR ;
Meyerson, M ;
Griffin, JD .
CANCER RESEARCH, 2005, 65 (19) :8968-8974
[12]   EGFR mutation and resistance of non-small-cell lung cancer to gefitinib [J].
Kobayashi, S ;
Boggon, TJ ;
Dayaram, T ;
Janne, PA ;
Kocher, O ;
Meyerson, M ;
Johnson, BE ;
Eck, MJ ;
Tenen, DG ;
Halmos, B .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (08) :786-792
[13]   Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib [J].
Kosaka, Takayuki ;
Yatabe, Yasushi ;
Endoh, Hideki ;
Yoshida, Kimihide ;
Hida, Toyoaki ;
Tsuboi, Masahiro ;
Tada, Hirohito ;
Kuwano, Hiroyuki ;
Mitsudomi, Tetsuya .
CLINICAL CANCER RESEARCH, 2006, 12 (19) :5764-5769
[14]   Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib [J].
Lynch, TJ ;
Bell, DW ;
Sordella, R ;
Gurubhagavatula, S ;
Okimoto, RA ;
Brannigan, BW ;
Harris, PL ;
Haserlat, SM ;
Supko, JG ;
Haluska, FG ;
Louis, DN ;
Christiani, DC ;
Settleman, J ;
Haber, DA .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (21) :2129-2139
[15]   Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib [J].
Mulloy, Roseann ;
Ferrand, Audrey ;
Kim, Youngjoo ;
Sordella, Raffaella ;
Bell, Daphne W. ;
Haber, Daniel A. ;
Anderson, Karen S. ;
Settleman, Jeffrey .
CANCER RESEARCH, 2007, 67 (05) :2325-2330
[16]   Detection of EGFR mutations in archived cytologic specimens of non-small cell lung cancer using high-resolution melting analysis [J].
Nomoto, Kiyoaki ;
Tsuta, Koji ;
Takano, Toshimi ;
Fukui, Tomoya ;
Yokozawa, Karin ;
Sakamoto, Hiromi ;
Yoshida, Teruhiko ;
Maeshima, Akiko Miyagi ;
Shibata, Tatsuhiro ;
Furuta, Koh ;
Ohe, Yuichiro ;
Matsuno, Yoshihiro .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2006, 126 (04) :608-615
[17]   EGFR mutations in lung cancer:: Correlation with clinical response to gefitinib therapy [J].
Paez, JG ;
Jänne, PA ;
Lee, JC ;
Tracy, S ;
Greulich, H ;
Gabriel, S ;
Herman, P ;
Kaye, FJ ;
Lindeman, N ;
Boggon, TJ ;
Naoki, K ;
Sasaki, H ;
Fujii, Y ;
Eck, MJ ;
Sellers, WR ;
Johnson, BE ;
Meyerson, M .
SCIENCE, 2004, 304 (5676) :1497-1500
[18]   Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain [J].
Pao, W ;
Miller, VA ;
Politi, KA ;
Riely, GJ ;
Somwar, R ;
Zakowski, MF ;
Kris, MG ;
Varmus, H .
PLOS MEDICINE, 2005, 2 (03) :225-235
[19]   EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib [J].
Pao, W ;
Miller, V ;
Zakowski, M ;
Doherty, J ;
Politi, K ;
Sarkaria, I ;
Singh, B ;
Heelan, R ;
Rusch, V ;
Fulton, L ;
Mardis, E ;
Kupfer, D ;
Wilson, R ;
Kris, M ;
Varmus, H .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (36) :13306-13311
[20]   Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors [J].
Politi, Katerina ;
Zakowski, Maureen F. ;
Fan, Pang-Dian ;
Schonfeld, Emily A. ;
Pao, William ;
Varmus, Harold E. .
GENES & DEVELOPMENT, 2006, 20 (11) :1496-1510